Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities.
Certepetide, Lisata’s proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.
Recent data from several trials, including the Phase 2b ASCEND study and the investigator-initiated CENDIFOX and iLSTA studies, showed encouraging signals in survival, response rates, and safety. Additional trial data are expected through early 2026.
During Q3, Lisata entered a global license agreement with Catalent, granting rights to evaluate certepetide as part of its SMARTag Antibody-Drug Conjugate (ADC) Technology Platform.
The company also announced a strategic alliance with GATC Health to leverage its Multiomics Advanced Technology artificial intelligence drug discovery platform to identify and optimize potential new therapies.
“Once again, the recent quarter saw the reporting of positive data from a number of clinical studies involving certepetide, including from the ASCEND, iLSTA, and CENDIFOX trials,” Lisata CEO Dr David Mazzo said in a statement. “Overall, it was a productive and positive quarter marked by our continued vigilance in managing expenses.”
Financial results
Lisata exited Q3 with no debt and expects its current cash balance to fund operations into early 2027.
The company reported operating expenses of $4.4 million for the third quarter, down 17.3% from $5.3 million a year earlier.
Research and development costs were $2 million, compared with $2.5 million in the prior-year quarter, while general and administrative expenses decreased to $2.5 million from $2.8 million.
The company posted a net loss of $4.2 million for the quarter, compared with a net loss of $4.9 million in the same period last year.